|Rat Target Sites||Mouse Target Sites||TD50 (mg/kg/day)|
|hmo(B) nrv(B) tba ubl(B)||hmo(B) nrv(B) tba ubl(B)||lun||hmo lun||2.21m,v||5.96i,m|
|Monkey Target Sites||TD50
|no positive||no positive||no positive||no positive|
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
CYCLOPHOSPHAMIDE (endoxan) 50-18-0 1657 M f swi ipj 26w79 1336 0 1.69mg 3.52mg Skipper;srfr;1976/Weisburger;canc;1977/Prejean pers.comm. --- lys e 7.09mg * P<.003 + 2.50mg 61.3mg 3/154 1/19 4/16 ski sqc e 11.1mg * P<.002 3.35mg 81.6mg 0/154 1/19 2/16 lun mix e 6.15mg * P<.06 + 1.97mg n.s.s. 20/154 4/19 5/16 liv lys e no dre P=1. 2.43mg n.s.s. 1/154 0/19 0/16 tba mal e 1.78mg * P<.0005 .858mg 5.93mg 29/154 7/19 11/16 tba mix e 1.78mg * P<.0005 .815mg 8.25mg 42/154 9/19 11/16 tba ben e no dre P=1. 6.99mg n.s.s. 13/154 2/19 0/16 1658 M m swi ipj 26w79 1336 0 1.72mg 3.52mg --- leu e 8.69mg * P<.004 2.63mg 84.8mg 0/101 2/22 1/9 lun mix e 5.78mg * P<.07 + 1.78mg n.s.s. 9/101 5/22 2/9 liv mix e 40.9mg * P<.5 4.60mg n.s.s. 2/101 0/22 1/9 tba mix e 3.66mg * P<.09 1.15mg n.s.s. 28/101 8/22 5/9 tba mal e 3.77mg * P<.05 1.27mg n.s.s. 19/101 7/22 4/9 tba ben e no dre P=1. 4.42mg n.s.s. 9/101 1/22 1/9 1659 P b cym eat 11y13 2003 : 0 3.46mg Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm. bre pam w 1.04mg P<.002 .245mg 16.0mg 0/32 2/3 hea car w 8.30mg P<.08 1.35mg n.s.s. 0/33 1/8 lun car w 8.30mg P<.08 1.35mg n.s.s. 0/33 1/8 ute ley Ww 8.30mg P<.08 1.35mg n.s.s. 0/33 1/8 tba mix Ww .818mg P<.0005 .234mg 4.62mg 0/33 4/8 tba ben Ww .922mg P<.0005 .240mg 7.54mg 0/33 3/8 tba mal Ww 8.30mg P<.08 1.35mg n.s.s. 0/33 1/8 1660 P b rhe eat 11y13 2003 : 0 2.94mg liv fbl w .436mg P<.007 71.0ug 82.2mg 0/42 1/1 liv hem w .436mg P<.007 71.0ug 82.2mg 0/42 1/1 bre pam Ww 5.67mg P<.05 .923mg n.s.s. 0/51 1/7 ubl tcc w 8.28mg P<.04 1.35mg n.s.s. 0/93 1/10 tba mix Ww 1.75mg P<.03 .341mg n.s.s. 5/108 3/12 tba ben Ww 2.29mg P<.08 .337mg n.s.s. 4/108 2/12 tba mal Ww 6.54mg P<.3 .769mg n.s.s. 2/93 1/10 1661 R m b46 ivj 12m24 1017 0 .929mg Schmahl;arzn,20,1461-1467;1970 tba mix es 3.01mg P<.04 + 1.12mg n.s.s. 7/65 10/36 tba mal es 5.36mg P<.1 + 1.62mg n.s.s. 4/65 6/36 tba ben es 9.02mg P<.3 2.12mg n.s.s. 3/65 4/36 1662 R b sda wat 32m36 1705 0 .221mg .450mg .893mg 1.79mg Schmahl;ijcn,23,706-712;1979 ubl tcc ae 21.4mg * P<.0005 + 12.1mg 70.4mg 0/74 2/77 2/78 5/73 8/72 --- mix ae 34.9mg * P<.2 + 12.1mg n.s.s. 0/74 3/77 6/78 6/73 4/72 vse hms ae 65.6mg * P<.3 17.1mg n.s.s. 1/74 4/77 2/78 7/73 3/72 liv tum ae 189.mg * P<.3 46.4mg n.s.s. 0/74 0/77 1/78 0/73 1/72 ner ngs ae no dre P=1. + 29.6mg n.s.s. 1/74 7/77 5/78 6/73 1/72 tba mal ae 12.8mg * P<.05 + 5.20mg n.s.s. 9/74 22/77 27/78 26/73 22/72 1663 R f sda ipj 24m24 1134 0 .571mg Schmahl;zkko,86,77-84;1976 mam mal es 1.70mg P<.05 .660mg n.s.s. 3/33 10/36 tba mal es 1.26mg P<.02 + .549mg n.s.s. 3/33 12/36 1664 R m sda ipj 25m25 1134 0 .571mg liv hae es no dre P=1. 3.91mg n.s.s. 1/36 0/32 tba mal es 2.87mg P<.06 + .956mg n.s.s. 1/36 5/32 1665 R m sda ivj 12m24 1703 0 .929mg Schmahl;zkko,81,211-215;1974 mix hae e 3.38mg P<.007 1.29mg 65.1mg 1/52 6/32 tba mal e 1.41mg P<.002 + .656mg 6.75mg 6/52 14/32
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.